Senzime AB (publ) (STO:SEZI)

Market Cap	677.60M +3.7%
Revenue (ttm)	103.76M +48.5%
Net Income	-125.27M
EPS	-0.82
Shares Out	157.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,159
Open	4.355
Previous Close	4.310
Day's Range	4.300 - 4.460
52-Week Range	3.850 - 7.380
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 16, 2026

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 59
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SEZI

Financial Performance

In 2025, Senzime AB's revenue was 104.02 million, an increase of 77.89% compared to the previous year's 58.48 million. Losses were -137.42 million, 15.7% more than in 2024.